BCLI Brainstorm Cell Therapeutics
- 0.620
- +0.053+9.35%
- 0.620
- 0.000-0.02%
Brainstorm Cell Therapeutics News
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment With NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn®).
Brainstorm Cell Therapeutics | 10-Q: Quarterly report
Brainstorm Cell Q1 2024 Adj EPS $(0.05) Beats $(0.07) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent.
Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire NEW YORK, May 14, 2024 Company received written agreement from the U.S. FDA und
Brainstorm Cell Therapeutics Shares Are Trading Lower After the Company Announced It Received a Letter From the Nasdaq Indicating That It Did Not Regain Compliance With the Minimum Bid Price Requirement.
Brainstorm Cell Therapeutics Shares Are Trading Lower After the Company Announced It Received a Letter From the Nasdaq Indicating That It Did Not Regain Compliance With the Minimum Bid Price Requireme
Brainstorm Cell Therapeutics Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement By April 29
Brainstorm Cell Therapeutics Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement By April 29
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u
Brainstorm Cell Therapeutics Executive Leadership Changes
BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Bob Dagher, MD, Promoted to Chief Medical OfficerDr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited clinical trial. The New York-based company,
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire NEW YORK, April 16, 2024 Bob Dagher, MD, Promoted to Chief Medical Off
BrainStorm Cell Therapeutics Regains Compliance With NASDAQ Minimum Market Value Rule
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today...
Brainstorm Cell Therapeutics Announced Peer-reviewed Publication Of Phase 3 Biomarker Data In Muscle And Nerve Suggesting That Debamestrocel Or NurOwn May Impact Key Biomarkers In Amyotrophic Lateral Sclerosis That Are Predictive Of Disease Progression
Brainstorm Cell Therapeutics Announced Peer-reviewed Publication Of Phase 3 Biomarker Data In Muscle And Nerve Suggesting That Debamestrocel Or NurOwn May Impact Key Biomarkers In Amyotrophic Lateral
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data From NurOwn's® Phase 3 Clinical Trial in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $230.5 million. Biophytis (NASD
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
Analysis
Price Target
No Data
